Quality of prescription drug use in patients with type 2 diabetes mellitus in Germany;Qualität der arzneimittelversorgung bei patienten mit diabetes mellitus typ 2 in Deutschland

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 21, 2003, Pages 1183-1186

  Rathmann, Wolfgang ^a,b   Giani, G ^a  

^a Klinische Biochemie   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; DRUG UTILIZATION; FEMALE; GERMANY; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; ADOLESCENT; DRUG COMBINATION; DRUG INTERACTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0038545223     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39357     Document Type: Review

References (19)

1. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Brit Med J 2000; 321: 412-419
2. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular diesase in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
3. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy. A case-control study. Neurology 2002; 58: 1333-1337
4. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 1995; 311: 293-295
5. Liebl A, Spannheimer A, Reitberger U, Wagenpfeil S, Görtz A. Aktuelles Diabetes-Management für Patienten mit Typ 2-Diabetes in Deutschland. Ergebnisse der CODE-2-Studie. Diab Stoffw 2002; 11: 55-61
6. Nielsen I, Icks A, Rathmann W, Haastert B, Giani G. Discontinuation of treatment after start of new course of antihypertensive drugs in diabetic patients with newly diagnosed hypertension. Pharmacoepidemiol Drug Safety 2002; 11: S146(Suppl 1)
7. Rathmann W, Haastert B, Roseman JM, Gries FA, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care 1998; 21: 389-397
8. Rathmann W, Haastert B, Roseman JM, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol 1999; 52: 1103-1109
9. Rathmann W. Costs and effectiveness of medications in diabetic patients. Drug Benefit Trends 1998; 10: 24-33
10. Rathmann W, Haastert B, Icks A et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000. Diabetologia 2003; 46: 182-189
11. Rothenbacher D, Rüter G, Saam S, Brenner H. Versorgung von Patienten mit Typ 2-Diabetes. Ergebnisse aus 12 Hausarztpraxen. Dtsch Med Wochenschr 2002; 127: 1183-1187
12. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 2000; 321: 405-412
13. Thefeld W. Prävalenz des Diabetes mellitus in der erwachsenen Bevölkerung Deutschlands. Gesundheitswesen 1999; 61: S85-S89 (Sonderheft 2)
14. Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
16. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J 1998; 317: 703-713
17. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J 1998; 317: 713-720
18. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138: 593-602
19. Wenzel U, Röben T, Schwietzer G, Stahl RAK. Die Therapie der arteriellen Hypertonie. Eine Umfrage bei niedergelassenen Ärzten. Dtsch Med Wochenschr 2001; 126: 1454-1459